Quell Therapeutics Expands Series A Financing to $84 Million

Quell Therapeutics Ltd (“Quell”), a biotechnology company developing engineered T regulatory (Treg) cell therapies, today announced the closing of an extended Series A financing led by their existing investors Syncona Ltd, who have committed an additional $34.7 million and UCL Technology Fund who have committed an additional $1 million; bringing the total Series A financing to circa $84 million.

Barny Cox, Senior Business Manager at UCLB: “The progress made by Quell in bringing together the knowledge and expertise of leading academic immunologists and building around them a strong and experienced team, together providing the capability for the rapid development of transformative Treg therapies targeting chronic medical conditions, is nothing short of impressive, and an illustration of the effective translation of academic research derived innovations from several institutions towards meaningful patient benefit.”

Read the announcement on the Quell Therapeutics website.